Do Psoriasis Treatments Prevent the Development of Psoriatic Arthritis?

The presentation discusses the critical question of whether psoriasis treatments can prevent the development of psoriatic arthritis (PSA). The speaker emphasizes the significant overlap between the treatment of psoriasis and PSA, noting that about 30-40% of psoriasis patients will eventually develop PSA. They explain the different stages leading from psoriasis to PSA, including preclinical and subclinical stages where patients may not yet exhibit symptoms. Current pharmacotherapies largely use shared biologics between both conditions, with only a couple of exceptions. The speaker addresses biases in existing research, such as protopathic bias (confounding caused by treating early symptoms of PSA) and survival bias (the longer psoriasis patients remain untreated, the greater their risk for developing PSA). By analyzing studies, they note that early intervention with specific medications like methotrexate could reduce PSA incidence. Recent literature suggests varying effectiveness among different classes of biologics in preventing PSA, with uncertainty still surrounding the exact mechanisms. The speaker stresses the need for further research, especially prospective studies, to clarify these associations and better understand how psoriasis treatments might influence the risk of developing PSA.